Medivation Inc

Medivation — JP Morgan Healthcare Conference 2016

42 slides from Medivation's conference presentation, Jan 11, 2016

  1. Slide 1: JP Morgan Healthcare Conference

    David Hung, M.D. Founder, President and CEO JP Morgan Healthcare Conference | January 11, 2016 NASDAQ: MDVN Exhibit 99.1

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation includes forward-looking statements concerning our business plans and prospects that are made pursuant to the safe harbor provisions of the federal securities laws. Forward-looking statements are any statements regarding future events or results, and may be identified b

  3. Slide 3: Medivation's Broad Commercial and Late-Stage Portfolio

    Medivation’s Broad Commercial and Late-Stage Portfolio *Based on Q3’15 WW net sales, as reported at the Astellas level. **PFS = Progression-free survival. XTANDI is a registered trademark of Astellas Pharma U.S. Inc.; Casodex is a registered trademark of the AstraZeneca group of companies; Lupron is

  4. Slide 4: Enzalutamide Prostate Cancer Opportunity

    Enzalutamide Prostate Cancer Opportunity

  5. Slide 5: The Largest XTANDI Opportunity Lies in Upstream Prostate Cancer

    The Largest XTANDI Opportunity Lies in Upstream Prostate Cancer Primarily Treated by the Urologist YR 1 2 14 DIAGNOSIS DEATH Primarily Oncologist Primarily Urologist DRx Chemo-naive Chemo PSA=0 Asymptomatic Symptoms 3 13 EMBARK and PROSPER are investigational ongoing studies; XTANDI is indicated for

  6. Slide 6: XTANDI Opportunity as Casodex Replacement

    XTANDI Opportunity as Casodex Replacement 1st Generation Hormonal Rx – Casodex (AR) and ketoconazole (cyp17) Next Generation Hormonal Rx – XTANDI (AR) and Zytiga (cyp17) Cyp17 inhibitors not widely used by urologists (steroids, LFT monitoring, etc.) Casodex: ketoconazole script ratio among urologist

  7. Slide 7: Incidence of Breast Versus Prostate Cancers Nearly Identical

    Incidence of Breast Versus Prostate Cancers are Nearly Identical at 550-600,000 Diagnoses per Year in G7 Markets *U.S., EU5 and Japan. Source: CancerMPact® Patient Metrics. Kantar Health. Available from www.cancermpact.com. Accessed 11 Nov 2015 2015 Projected Incidence in G7* Breast Cancer 580,000 P

  8. Slide 8: Novel Breast Cancer Drug Approvals Predate Prostate Cancer Drugs by 12+ Years

    Novel Breast Cancer Drug Approvals (Herceptin®) Predate Novel Prostate Cancer Drugs by 12+ Years $14B $12B $10B $8B $6B $4B $2B WW REVENUES Approved September 1998 $2B total revenue in chemo & hormones Approval of first novel agents in prostate cancer $2B total revenue 1st gen hormones Prostate Canc

  9. Slide 9: Far More Breast Cancer Drugs than Prostate Cancer Drugs

    ≤1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 Far More Breast Cancer Drugs than Prostate Cancer Drugs Prostate Zytiga XTANDI Only 2 of the approved prostate cancer therapies have demonstrated both PFS and OS benefits with a broad (pre- and post-chemo) lab

  10. Slide 10: Enzalutamide Breast Cancer Opportunity

    Enzalutamide Breast Cancer Opportunity

  11. Slide 11: Triple Negative Breast Cancer (TNBC) Opportunity

    TNBC comprises ~20% of all metastatic breast cancer Standard of care = chemotherapy ~50% of TNBC patients test positive for Medivation’s proprietary diagnostic genomic signature, which may correlate with enzalutamide responsiveness In a Phase 2 trial, patients on enzalutamide whose tumors tested Dx(

  12. Slide 12: Overall Survival by Dx Status in TNBC

    Overall Survival by Dx Status in TNBC 13.8-month Longer Median Survival Duration with Enzalutamide in Dx(+) Data cut off 15 Sept 2015; 118 patients in ITT population Dx (+) mOS 21.3 months Dx (-) mOS 7.5 months *Adjusted p-value is reported as part of the exploratory multi-covariate model that also

  13. Slide 13: Enzalutamide Breast Cancer Opportunity

    Enzalutamide Breast Cancer Opportunity Metastatic Breast Cancer by Sub-Type HR+, HER2- 50% HER2+,HR- 15% TNBC 20% 90% urologists US, EU5, and Japan, Stage IV 1L Patients MDVN internal analysis; CancerMPact® Patient Metrics and Treatment Architecture. Kantar Health. Available from www.cancermpact.com

  14. Slide 14: Enzalutamide Ph2 Trials in Larger Breast Cancer Populations

    Enzalutamide Ph2 Trials in Larger Breast Cancer Populations Anticipated to Have Data Readout 2H 2016 ER/PgR+ and HER2 Normal trial initiated in Dec. 2013; HER2 Amplified trial initiated start up activities in Aug 2014. ER/PgR+ and HER2 Normal DATA READOUT 2H 2016 GOAL Determine potential clinical be

  15. Slide 15: Enzalutamide Opportunity in Other Areas

    Enzalutamide Opportunity in Other Areas

  16. Slide 16: Enzalutamide Phase 2 Liver Cancer Trial Underway

    Enzalutamide Phase 2 Liver Cancer Trial Underway HCC is the most common hepatobiliary malignancy representing > 80% of all liver cases* *Kantar treatment architecture GOAL Evaluate potential benefit of enzalutamide in patients with advanced HCC who have failed or were intolerant to sorafenib or othe

  17. Slide 17: 2016 Milestones: Enzalutamide

    2016 Milestones: Enzalutamide 1H 2H ENZALUTAMIDE Phase 3 mHSPC Initiate Phase 4 PLATO Top-line data Phase 3 TNBC Initiate Phase 2 ER/PR+ & HER2 normal breast cancer Top-line data Publications in TERRAIN and STRIVE Publications Expanded urology and oncology sales force Expand mCRPC XTANDI® (enzalutam

  18. Slide 18: Talazoparib (MDV3800) Opportunity

    Talazoparib (MDV3800) Opportunity

  19. Slide 19: Anti-Tumor Mechanism Behind PARP Inhibition

    Cancers have frequent errors in DNA repair and often struggle to replicate their DNA Cancers that cannot repair and replicate their DNA will die PARP is a major DNA repair pathway; Inhibiting PARP can push CAs “over the edge” Because cancers have more DNA repair defects than normal cells, PARP inhib

  20. Slide 20: PARP Inhibition Inhibits SS DNA Break Repair

    PARP Inhibition Inhibits SS DNA Break Repair; Double Strand Break Repair Requires Homologous Recombination BER: base excision repair NHEJ: Non-homologous end joining NER: nucleotide excision repair MGMT: methyl guanine methyl transferase Lord and Ashworth Nature 2012;481:287-294.

  21. Slide 21: PARP Inhibitors Have Demonstrated Striking Effects in HRD

    PARP Inhibitors Have Demonstrated Striking Effects in HRD, Even in Heavily Pretreated, Refractory Patients Extremely Advanced Metastatic Prostate Cancer Patients dosed 50 Evaluable for response 49 Prior lines of treatment n (%) Docetaxel 50 (100%) Cabazitaxel 29 (58%) Abiraterone* 48 (96%) Enzalutam

  22. Slide 22: Response to PARP Inhibitor Olaparib in mCRPC

    ID Maximum % decline in PSA from baseline Measurable disease at baseline Best RECIST response Confirmed CTC conversion Baseline CTC count (7.5ml blood) Maximum % CTC decline Time on Treatment (weeks; ≥24 in bold) #1 84.7 No No 87 100 73 #5 51.2 No Yes 24 100 56+ #6 29.3 Yes SD Yes 105 97.1 16* #8 47

  23. Slide 23: Talazoparib's Highly Potent Effects in HRD Tumors

    Talazoparib’s Highly Potent Effects in Tumors with Homologous Recombination Deficiency (HRD) Increases BRCA-Deficient Breast Cancer Xenograft Death vs Olaparib MX-1 tumor cells Talazoparib 0.1 mg/kg Talazoparib 0.33 mg/kg Olaparib 100 mg/kg Shen et al. Clin Cancer Res 2013; 19:5003–15.

  24. Slide 24: Current Clinical Dose of PARP Inhibitors in Development

    Current Clinical Dose of PARP Inhibitors in Development Talazoparib (BMN673 now MDV3800), 1 mg QD Olaparib (AstraZeneca), 400 mg BID, 16 pills per day Veliparib (Abbvie), 400 mg BID Rucaparib (Clovis), 600 mg BID Niraparib (Tesaro), 300 mg QD 24

  25. Slide 25: PARP Inhibitors Work by 2 Pathways

    Figure modified from Murai et al., Cancer Research (2012) PARP Inhibitors Work by 2 Pathways: 1) Inhibition of PARP Enzyme Activity and 2) PARP Trapping (More Important) Cell death in HR deficient cells Enhanced cell death in any tumor cell with single strand DNA damage Chemotherapy (eg. temozolomid

  26. Slide 26: Talazoparib is 4-8 Fold More Potent at Inhibiting PARP1

    Pathway 1: Talazoparib is a 4-8 Fold More Potent at Inhibiting PARP1 Enzyme Activity than Other PARP Inhibitors Relative Potency for PARP1 Inhibition PARP1 enzyme assay: incorporation of biotinylated PAR onto histone proteins in a 96-well strip well format using recombinant human PARP1 (Trevigen) Ce

  27. Slide 27: PARP-Trapping May be More Important than Enzyme Inhibition

    Figure modified from Murai et al., Cancer Research (2012) PARP-Trapping may be More Important than Enzyme Inhibition, and Differs Greatly Among PARP Inhibitors Cell death in HR deficient cells Enhanced cell death in any tumor cell with single strand DNA damage Chemotherapy (eg. temozolomide, irinote

  28. Slide 28: Talazoparib Traps PARP1- and PARP2-DNA Complexes

    Talazoparib Traps PARP1- and PARP2-DNA Complexes and Potentiates Chemo Better than Olaparib and Rucaparib Western blot of chromatin with prostate cancer DU145 cells Murai et al. Mol Cancer Ther 2014; 13: 433–43 Talazoparib Olaparib

  29. Slide 29: PARP Trapped on SS and DS DNA Breaks

    PARP Trapped on SS and DS DNA Breaks Makes Them Harder to Repair, Even with +Homologous Recombination BER: base excision repair NHEJ: Non-homologous end joining NER: nucleotide excision repair MGMT: methyl guanine methyl transferase Lord and Ashworth Nature 2012;481:287-294.

  30. Slide 30: Talazoparib is a More Potent PARP Inhibitor and Unique PARP Trapper

    Talazoparib is a More Potent PARP Inhibitor (Pathway 1) and Unique PARP Trapper/Chemo-Potentiator (Pathway 2) Relative Potency for PARP1 Inhibition Relative Potency for Tumor Cell Killing Temozolomide Potentiation PARP1 enzyme assay: incorporation of biotinylated PAR onto histone proteins in a 96-we

  31. Slide 31: Talazoparib Potentiates Temozolomide in Small Cell Lung Cancer Xenografts

    Talazoparib Potentiates Temozolomide Tumor Kill in Small Cell Lung Cancer Xenografts at Submaximal Doses Vehicle Temozolomide 3mg/kg PO QD x 4 Talazoparib 0.25 mg/kg PO QD x 4 Talazoparib + Temozolomide Medivation; data on file

  32. Slide 32: Over 500,000 Patients Treated with DNA-Damaging Chemo Agents

    Over 500,000 Patients Were Treated with DNA-Damaging Chemo Agents in the U.S. in 2014 IMS Syndicated Oncology Tracker (patient level medical and pharmacy claims).

  33. Slide 33: Radiosensitization by Talazoparib of Head and Neck Cancer Cells

    Radiosensitization by Talazoparib of Head and Neck Cancer Cells Occurs at Submaximal Doses Wong et al. Potent anti-tumor activity of talazoparib (BMN673) in combination with radiation for squamous cell carcinoma of the head and deck. AACR 2015.

  34. Slide 34: Over 500,000 Patients Treated with Radiation Therapy in 2014

    Over 500,000 Patients Were Treated with Radiation Therapy in the U.S. in 2014 CancerMPact® Patient Metrics. Kantar Health. Available from www.cancermpact.com. Accessed September 3, 2015.

  35. Slide 35: Off-Target Cell Toxicity Lower with Talazoparib

    Non-Specific Off-Target Cell Toxicity is Lower with Talazoparib than with Olaparib and Rucaparib Murai et al. Mol Cancer Ther 2014; 13: 433–43 DT40: PARP1-/- avian B lymphoblast cells are equivalent to PARP1 and PARP2 double knockout cells and do not have detectable levels of PARP Talazoparib

  36. Slide 36: Talazoparib Development Studies Targeted for 2016

    Talazoparib Development Studies Targeted for 2016 Breast Cancer (beyond gBRCA mutations) Prostate Cancer (post-docetaxel) Small Cell Lung Cancer (maintenance and/or later lines) Additional details on study designs to be provided at time of trial initiation Ovarian Cancer (late stage) Colorectal Canc

  37. Slide 37: Phase 3 EMBRACA Expected to Complete Enrollment in Q4 2016

    Phase 3 EMBRACA Expected to Complete Enrollment in Q4 2016 Enrollment Initiated in October 2013 EMBRACA Talazoparib Breast Cancer Trial GOAL Compare PFS of patients treated with monotherapy talazoparib relative to those treated with protocol-specified physician’s choice single agent chemotherapy Up

  38. Slide 38: Pidilizumab (MDV9300) Opportunity

    Pidilizumab (MDV9300) Opportunity

  39. Slide 39: Pidilizumab (MDV9300) – Immune Oncology MAb

    Exclusive WW rights from CureTech, Ltd., in Q4 2014, for all potential indications Administered to several hundred patients and activity demonstrated in multiple Phase 2 trials (eg. 52% complete response rate in B-Cell Lymphoma) Pidilizumab effects on DLBCL published in Journal of Clinical Oncology

  40. Slide 40: Pivotal Trial Initiated in Diffuse Large B-Cell Lymphoma

    Pivotal Trial Initiated in Diffuse Large B-Cell Lymphoma Enrollment Initiated in December 2015 Pidilizumab DLBCL Trial GOAL Determine best overall response rate in patients with an incomplete response following salvage therapy or autologous stem cell transplantation ~180 patients Two parallel cohort

  41. Slide 41: MDV4463: Novel SREBP Pathway Inhibitor

    MDV4463 is a novel small molecule inhibitor of the sterol regulatory element binding proteins (SREBP) pathway SREBPs are master regulators of cholesterol and lipid biosynthesis Modulates the expression of multiple metabolic proteins including, HMG-CoA reductase, the target of all statins Preclinical

  42. Slide 42: Why We Are Here—Graeme's Story

    Why We Are Here—Graeme’s Story

Medivation — JP Morgan Healthcare Conference 2016 on 6ix